ClinicalTrials.gg
CompletedNCT06496217Updated Oct 28, 2025

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

A Phase 1 interventional study of MBX 2109 and MBX 2109 in Renal Impairment, sponsored by MBX Biosciences. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by MBX Biosciences · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
290th of 468
25 · median 32
Started
2024
with 19 others
Phase 1
232 of 553
14 open now
Registered
508th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 290th largest by enrollment of the 468 interventional ones that give a count, is one of 20 that started in 2024, is one of 232 in phase 1, and was the 508th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function

Read the detailed description

A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness to adhere to the Protocol requirements as evidenced by a signed and dated form (ICF)
  2. Subject is, as stated and in the opinion of the Investigator, willing and able to comply with the study drug regimen and all other study procedures and requirements, and is available for the duration of the study
  3. Adult male or female, of at least 18 years of age, but not older than 80 years
  4. Subject is willing to comply with the requirements.
  5. ≥ 18.5 kg/m2 and \< 40.0 kg/m2 at the time of Screening.
  6. Light-, non- or ex-smoker
  7. Has suitable venous access for blood sampling

    Subjects with Normal Renal Function (Group 4):

  8. Medically healthy, in the opinion of an Investigator, with clinically insignificant Screening results (eg, laboratory profiles, medical history, vital signs, , physical examination)
  9. Normal renal function with ≥ 90 mL/min at Screening
  10. Must match to the pooled mean age (± 10 years), BMI (within 20%) and gender (ratio should be similar) of mild, moderate, and severe (if applicable) renal impaired subjects at Screening.

    Subjects with Mild, Moderate, and Severe Renal Impaired Function (Groups 1, 2, and 3):

  11. Considered clinically stable in the opinion of an Investigator
  12. Presence of mild renal impairment (eGFR ≥ 60 and \<90 mL/min), moderate renal impairment (eGFR ≥ 30 and \<60 mL/min), or severe renal impairment (eGFR \<30 mL/min) or kidney failure not receiving dialysis, at Screening: renal impairment should have been stable for at least 1 month prior to Screening.

Exclusion criteria

Exclusion Criteria (All Participants)

  1. Female who is lactating or breastfeeding
  2. Female who is pregnant according to the pregnancy test at Screening or prior to study drug administration or planning to become pregnant before 90 days after the last study drug administration.
  3. History of significant to MBX 2109 or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
  4. History of, or positive test for surface antigen (HbsAg), antibody (HCV Ab), or antibody, at Screening.
  5. Presence or history of any disorder that could interfere with completion of the study based on the opinion of an Investigator.
  6. Intake of MBX 2109, or any product (IP) in the 28 days prior to study drug administration.
  7. Have urinary incontinence without catheterization
  8. Receipt of blood products within 3 months prior to study drug administration.
  9. Donation of 50 mL or more of blood in the 28 days prior to study drug administration
  10. Donated 500 mL or more of blood within 56 days prior to study drug administration
  11. Donated plasma within 2 weeks prior to Screening or donated within 6 weeks prior to Screening.
  12. Immunization with a Coronavirus Disease 2019 (COVID-19) vaccine in the 14 days prior to the first study drug administration.
  13. Scheduled immunization with a COVID-19 vaccine during the study that, in the opinion of an Investigator, could potentially interfere with subject participation, subject safety, study results, or any other reason.
  14. Use of St. John's wort in the 28 days prior to the first study drug administration.
  15. Inclusion in a previous group for this clinical study
  16. Any skin condition and/or tattoo that may interfere with the injection site evaluation.

    Subjects with Normal Renal Function (Group 4):

  17. Presence of significant gastrointestinal, liver, or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs or known to potentiate or predispose to undesired effects.
  18. History of significant gastrointestinal, liver, or kidney disease that may affect drug bioavailability.
  19. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease.
  20. Presence of abnormalities at the Screening visit, as defined by medical judgment.
  21. Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first study drug administration.
  22. Supine or semi-supine blood pressure below 90/50 mmHg at the Screening visit
  23. Supine or semi-supine blood pressure higher than 140/90 mmHg at the Screening visit (blood pressure readings greater than 140/90 mmHg may be retested if completed thought to be influenced by stress, at the discretion of the Investigator).
  24. Supine or semi-supine pulse rate less than 40 beats per minute (bpm) or more than 100 bpm at Screening.
  25. Any clinically significant illness in the 28 days before Day 1 of the study
  26. Use of any prescription drugs (with the exception of hormonal or hormone replacement therapy) in the 28 days before Day 1 of the study.
  27. Use of over-the-counter (OTC) drugs and natural health products (eg, herbal remedies) at least 7 days (or 5-times the half-life of the drug, if longer) prior to study drug administration.
  28. Use of any enzyme-modifying drugs, or drugs with effects on membrane transporters, including any strong cytochrome P450 3A4 and P-glycoprotein inducers and inhibitors in the previous 28 days before Day 1 of the study.

    Subjects with Mild, Moderate, and Severe Renal Impaired Function (Groups 1, 2, and 3):

  29. History of renal transplant
  30. Supine or semi-supine blood pressure below 90/50 mmHg at the Screening visit.
  31. Supine or semi-supine blood pressure higher than 180/110 mmHg at the Screening visit.
  32. Supine or semi-supine pulse rate less than 45 bpm or more than 110 bpm at Screening.
  33. History or presence, in the opinion of an Investigator, of significant clinically unstable respiratory, cardiovascular, pulmonary, hepatic, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
  34. Presence of poorly controlled Type 1 or Type 2 diabetes as defined by > 10%.
  35. Presence of clinically significant physical examination, laboratory test, or ECG finding that, in the opinion of an Investigator and/or Sponsor, may interfere with any aspect of study conduct or interpretation of results.
  36. Subjects requiring treatment for renal impairment or other chronic disease (eg, well controlled diabetes, hypertension) must be on a stable treatment plan (medicines, doses, and regimens) for at least 14 days (except insulin) prior to study drug administration and during the entire study.
  37. Positive Screening of alcohol and/or drugs of abuse at Screening or prior to study drug administration unless results can be explained by a prescription medication.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Single 900 µg dose of MBX 2109

    A single, 900 µg dose of MBX 2109 will be administered subcutaneously in the abdomen

    Drug: MBX 2109

Interventions

  • Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)

  • Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)

  • Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis

  • Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)

    Assess the plasma pharmacokinetics (PK) of MBX 2109 and MBX 2099 following a single 900 µg subcutaneous (SC) dose

    Time frame: Baseline through Day 36

  2. Maximum observed concentration (Cmax)

    Assess the plasma pharmacokinetics (PK) of MBX 2109 and MBX 2099 following a single 900 µg subcutaneous (SC) dose

    Time frame: Baseline through Day 36

  3. Area under the plasma concentration-time curve from time 0 to time of last quantifiable sample (AUC0-T)

    Assess the plasma pharmacokinetics (PK) of MBX 2109 and MBX 2099 following a single 900 µg subcutaneous (SC) dose

    Time frame: Baseline through Day 36

  4. Apparent clearance (CL/F) (MBX 2109 only)

    Assess the plasma pharmacokinetics (PK) of MBX 2109 and MBX 2099 following a single 900 µg subcutaneous (SC) dose

    Time frame: Baseline through Day 36

  5. Time to maximum concentration (Tmax)

    Assess the plasma pharmacokinetics (PK) of MBX 2109 and MBX 2099 following a single 900 µg subcutaneous (SC) dose

    Time frame: Baseline through Day 36

  6. Terminal elimination half-life (t1/2)

    Assess the plasma pharmacokinetics (PK) of MBX 2109 and MBX 2099 following a single 900 µg subcutaneous (SC) dose

    Time frame: Baseline through Day 36

  7. Apparent volume of distribution (Vz/F) (MBX 2109 only)

    Assess the plasma pharmacokinetics (PK) of MBX 2109 and MBX 2099 following a single 900 µg subcutaneous (SC) dose

    Time frame: Baseline through Day 36

07

Study locations

3 sites
  • MBX Biosciences Investigational Site
    Miami, Florida 33136, United States
  • MBX Bioscience Investigational Site
    Tampa, Florida 33603, United States
  • MBX Biosciences Investigational Site
    Minneapolis, Minnesota 55101, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Sep 2025, 14 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 14 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jul 11, 2024
StartActual
Jun 13, 2024
Primary completionActual
Sep 4, 2025
CompletionActual
Sep 4, 2025
Last update
Oct 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06496217
Lead sponsor
MBX Biosciences
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Jun 13, 2024
Primary completion
Sep 4, 2025
Completion
Sep 4, 2025
Last update
Oct 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Canvuparatide

Start the discussion